Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Dr. Reddy's Laboratories Ltd RDY

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NYSE:RDY)

Fundamentals Snapshot (NYSE:RDY)

Current News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

Business Wire September 7, 2022

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

Business Wire July 29, 2022

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Business Wire July 27, 2022

Dr. Reddy's Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Business Wire July 22, 2022

Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

Business Wire July 8, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

Business Wire July 5, 2022

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

Business Wire June 24, 2022

Eton Pharmaceuticals Announces Sale of Hospital Products

GlobeNewswire June 24, 2022

Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

Business Wire June 14, 2022

Opinion & Analysis (NYSE:RDY)

No current opinion is available.

Bullboard Posts (NYSE:RDY)

Drill program?

Looks like an internet project...anyone know if they have a drill program going?  
unclescrooge07 - January 14, 2021

Fast mover

This stock has the potential to move very quickly they have a very low share count trdeable and each PP carries a one dollar warrant...
GMAN66 - January 12, 2021

RDY is live

Good first day of trading! Close at .49 which is 11 cents under the pp at .60...these guys have done a great job getting thia together in...
GMAN66 - January 12, 2021

Looks like it is out ! Congrats to all -Quick question

TDAmeritrade is showing RDY.CN in my account reflecting the correct number of shares post split . I am a customer of TD in USA, it use to...
ctblizzard - January 12, 2021

RE:Starts trading tomorrow

Thank you!
ctblizzard - January 11, 2021

Starts trading tomorrow

EOM
YoungInvestor89 - January 11, 2021